bexarotene


Also found in: Wikipedia.

bexarotene

 [bek-sar´ah-tēn]
a retinoid that modulates transcription and expression of genes involved in cellular differentiation and proliferation; used as an antineoplastic in the treatment of cutaneous T-cell lymphoma, administered orally. It is also used topically in the treatment of cutaneous lesions of T-cell lymphomas and Kaposi's sarcoma.

bexarotene

/bex·ar·o·tene/ (bek-sar´ah-tēn) a retinoid used as an antineoplastic in the treatment of cutaneous T-cell lymphoma and the cutaneous lesions of T-cell lymphomas and Kaposi's sarcoma.

bexarotene

a second-generation retinoid.
indications This drug is prescribed for cutaneous T cell lymphoma. Investigational uses include treatment of breast cancer.
contraindications Pregnancy and known hypersensitivity to retinoids prohibit bexarotene's use.
adverse effects Life-threatening adverse reactions include acute pancreatitis, leukopenia, and neutropenia. Other serious side effects include asthenia, infection, anemia, and hypothyroidism. Among the drug's common side effects are headache, nausea, abdominal pain, and diarrhea.

bexarotene

A retinoid that binds to retinoid X receptors, upregulating their activity by either removing negative transcription control or by facilitating transcription. It is FDA-approved for treating cutaneous T cell lymphoma, and has been used off label for lung and breast cancer, and Kaposi sarcoma.
Adverse effects Similar to hypervitaminosis A—headache, nausea, vomiting, lip inflammation, mucous-membrane dryness, joint pain, scaly skin, hyperlipidaemia
References in periodicals archive ?
Exclusive supply medications: bexarotene, for establishments involved in the Platform for Health Logistics in Seville.
The high profile 2012 study in the US journal Science found that mice treated with bexarotene became rapidly smarter and the plaque in their brains that was causing Alzheimer's started to disappear within hours.
The research reviewed previously published findings on the drug bexarotene, approved by the US Food and Drug Administration for use in cutaneous T cell lymphoma.
The University of Pittsburgh Graduate School of Public Health research, funded by the National Institutes of Health's National Institute on Aging and Alzheimer's Association, reviewed previously published findings on the drug bexarotene, approved by the US Food and Drug Administration for use in cutaneous T cell lymphoma.
Then, reading the caption I see that the second photo is "the brain of a similar mouse after three days of bexarotene treatment.
67) Another phase 2 clinical study enrolled 74 patients with CTCL for whom 2 or more prior systemic therapies had failed, 1 of which was bexarotene.
announced today that they have concluded a license agreement concerning bexarotene (generic name), a treatment for cutaneous T-cell lymphoma (CTCL).
According to the study in the journal Science, when neuroscientists at Case Western Reserve University School of Medicine in Cleveland used the cancer drug bexarotene on mice, they found it cleared a naturallyoccurring protein called amyloid, which is associated with Alzheimer's, from their brains.
Bexarotene, normally used to treat cancer, helped rid mice of hallmark proteins in the brain associated with the memory loss illness.
A team in the US have found that the drug Bexarotene, which is normally used to treat cancer, can quickly reverse symptoms in mice.
In chapter 3, one of the editors, Anders Vahlquist, traces the development of the use of oral retinoids (etretinate, acitretin, bexarotene, isotretinoin) in dermatology.
Examples of these are the enzymes asparaginase and pegaspargase; ribonucleotide reductase inhibitor hydroxyurea; retinoids bexarotene, isotretinoin and tretinoin.